Leerink initiated coverage of Lumexa Imaging (LMRI) with an Outperform rating and $23 price target The firm says Lumexa possesses many powerful secular growth themes anchored to evolving technology, growth and a favorable shift in advanced imaging, low-cost outpatient care, and demographic tailwinds. Leerink forecasts a 30% increase in new imaging centers by 2030 which elevates the case for accelerating organic growth. The company’s unique and aspirational JV model aligns strongly with health system ambulatory priorities, the firm adds. Leerink believes Lumexa carries the potential to be a double-digit compounding EBITDA grower over time.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LMRI:
- Lumexa Imaging initiated with an Outperform at Raymond James
- Lumexa Imaging initiated with an Outperform at William Blair
- Lumexa Imaging initiated with an Overweight at Wells Fargo
- Lumexa Imaging Holdings: Capitalizing on Outpatient Imaging Tailwinds with Sustainable Growth and Attractive Risk-Reward
- Lumexa Imaging initiated with a Buy at Jefferies